论文部分内容阅读
报告１７４例不能手术切除的中、晚期肝癌肝动脉栓塞化疗（ＨＡＣＥ）和动脉内药物灌注（ＨＡＩＣ）疗效观察比较分析。ＨＡＣＥ组９６例，ＨＡＩＣ组７８例，近期疗效有效率分别为８７．３％和６２．２％，１年、２年、３年生存率前者为４６．７％、２５．０％、３．１％，后者为１４．１％、０％、０％，ＨＡＣＥ组Ⅱ期手术切除５例，１例生存期已超过６年（未手术）。并发症和副反应以ＨＡＣＥ组为重。作者阐述了ＨＡＣＥ较ＨＡＩＣ疗效好的理论依据，对ＨＡＣＥ的禁忌证、治疗间隔时间作了讨论。认为门脉癌栓不是栓塞化疗的禁忌证，严重的肝功能损害才是禁忌证。间隔时间以肿瘤病灶和机体状况按各人不同情况具体安排，一般３月左右
174 cases of unresectable hepatocellular arterial chemoembolization (HACE) and intraarterial drug infusion (HAIC) were compared and analyzed. There were 96 cases in HACE group and 78 cases in HAIC group. The effective rate of curative effect was 87.3% and 62.2% respectively. The 1-year, 2-year and 3-year survival rates were 46.7%, 25.0%, and 3. 1%, the latter was 14.1%, 0%, 0%, 5 cases of HACE group II surgical resection, 1 case of survival has been more than 6 years (without surgery). Complications and side effects were focused on the HACE group. The authors elaborated the theoretical basis for the efficacy of HACE compared with HAIC, and discussed the contraindication and treatment interval of HACE. It is considered that portal vein cancer embolism is not a contraindication to embolization chemotherapy, and severe liver damage is a contraindication. The interval time is based on the different conditions of the tumor and the condition of the body, usually around March.